- Home
- CBAT vs PLX Comparison
CBAT vs PLX Comparison
Compare CBAT & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBAT
- PLX
- Stock Information
- Founded
- CBAT 1999
- PLX 1993
- Country
- CBAT China
- PLX United States
- Employees
- CBAT N/A
- PLX N/A
- Industry
- CBAT Industrial Machinery/Components
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CBAT Miscellaneous
- PLX Health Care
- Exchange
- CBAT Nasdaq
- PLX Nasdaq
- Market Cap
- CBAT 102.5M
- PLX 122.6M
- IPO Year
- CBAT N/A
- PLX 1998
- Fundamental
- Price
- CBAT $1.17
- PLX $1.55
- Analyst Decision
- CBAT
- PLX Strong Buy
- Analyst Count
- CBAT 0
- PLX 1
- Target Price
- CBAT N/A
- PLX $15.00
- AVG Volume (30 Days)
- CBAT 265.7K
- PLX 1.2M
- Earning Date
- CBAT 08-08-2025
- PLX 08-13-2025
- Dividend Yield
- CBAT N/A
- PLX N/A
- EPS Growth
- CBAT N/A
- PLX N/A
- EPS
- CBAT 0.00
- PLX 0.05
- Revenue
- CBAT $152,731,078.00
- PLX $59,764,000.00
- Revenue This Year
- CBAT $28.79
- PLX $65.02
- Revenue Next Year
- CBAT $36.77
- PLX $57.34
- P/E Ratio
- CBAT $281.10
- PLX $31.98
- Revenue Growth
- CBAT N/A
- PLX 0.18
- 52 Week Low
- CBAT $0.57
- PLX $0.82
- 52 Week High
- CBAT $1.45
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- CBAT 58.95
- PLX 47.41
- Support Level
- CBAT $1.13
- PLX $1.32
- Resistance Level
- CBAT $1.24
- PLX $1.67
- Average True Range (ATR)
- CBAT 0.06
- PLX 0.11
- MACD
- CBAT -0.01
- PLX 0.04
- Stochastic Oscillator
- CBAT 55.56
- PLX 62.86
About CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.